CN103501785B - 用于治疗脑肿瘤的csf-1r抑制剂 - Google Patents
用于治疗脑肿瘤的csf-1r抑制剂 Download PDFInfo
- Publication number
- CN103501785B CN103501785B CN201280021878.2A CN201280021878A CN103501785B CN 103501785 B CN103501785 B CN 103501785B CN 201280021878 A CN201280021878 A CN 201280021878A CN 103501785 B CN103501785 B CN 103501785B
- Authority
- CN
- China
- Prior art keywords
- purposes
- compound
- tumor
- csf
- blz945
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[n]1ncc(-c2nccc(Oc3ccc4nc(**(CCCC5)[C@@]5O)[s]c4c3)c2)c1 Chemical compound C[n]1ncc(-c2nccc(Oc3ccc4nc(**(CCCC5)[C@@]5O)[s]c4c3)c2)c1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482723P | 2011-05-05 | 2011-05-05 | |
| US61/482,723 | 2011-05-05 | ||
| US201261624861P | 2012-04-16 | 2012-04-16 | |
| US61/624,861 | 2012-04-16 | ||
| PCT/US2012/036589 WO2012151523A1 (en) | 2011-05-05 | 2012-05-04 | Csf-1r inhibitors for treatment of brain tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103501785A CN103501785A (zh) | 2014-01-08 |
| CN103501785B true CN103501785B (zh) | 2016-10-26 |
Family
ID=46062775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280021878.2A Active CN103501785B (zh) | 2011-05-05 | 2012-05-04 | 用于治疗脑肿瘤的csf-1r抑制剂 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20140065141A1 (enExample) |
| EP (1) | EP2704713B1 (enExample) |
| JP (1) | JP6046702B2 (enExample) |
| KR (1) | KR101938431B1 (enExample) |
| CN (1) | CN103501785B (enExample) |
| BR (1) | BR112013028095B1 (enExample) |
| CA (1) | CA2834696C (enExample) |
| CY (1) | CY1119642T1 (enExample) |
| DK (1) | DK2704713T3 (enExample) |
| EA (1) | EA023999B1 (enExample) |
| ES (1) | ES2622527T3 (enExample) |
| HR (1) | HRP20170593T1 (enExample) |
| HU (1) | HUE032754T2 (enExample) |
| LT (1) | LT2704713T (enExample) |
| MX (1) | MX347616B (enExample) |
| PL (1) | PL2704713T3 (enExample) |
| PT (1) | PT2704713T (enExample) |
| SI (1) | SI2704713T1 (enExample) |
| WO (1) | WO2012151523A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014147631A1 (en) * | 2013-03-22 | 2014-09-25 | Natco Pharma Limited | Formulation comprising gefitinib as oral suspension |
| EP3294417B1 (en) | 2015-05-08 | 2021-10-13 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of glioma |
| CN113940996A (zh) * | 2015-05-27 | 2022-01-18 | Ucb生物制药私人有限公司 | 用于治疗神经系统疾病的方法 |
| EP3973988A1 (en) | 2015-11-04 | 2022-03-30 | Duke University | Combination therapy of immunotoxin and checkpoint inhibitor |
| WO2018069893A1 (en) * | 2016-10-14 | 2018-04-19 | Novartis Ag | Methods for treating ocular disease using inhibitors of csf-1r |
| ES2949414T3 (es) * | 2016-10-14 | 2023-09-28 | Novartis Ag | Formas cristalinas de 4-(2-((1R,2R)-2-hidroxiciclohexilamino)benzotiazol-6-iloxi)-N-metilpicolinamida |
| US20190292246A1 (en) | 2016-11-03 | 2019-09-26 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia imhibitor |
| KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| CN111201438A (zh) | 2017-06-02 | 2020-05-26 | 朱诺治疗学股份有限公司 | 与和细胞疗法相关的毒性有关的制品和方法 |
| WO2019006427A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES |
| EP3676403A1 (en) | 2017-09-01 | 2020-07-08 | Juno Therapeutics, Inc. | Gene expression and assessment of risk of developing toxicity following cell therapy |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| WO2020036987A1 (en) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
| FI3886875T3 (fi) | 2018-11-30 | 2024-07-23 | Juno Therapeutics Inc | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä |
| ES2986007T3 (es) | 2018-11-30 | 2024-11-08 | Juno Therapeutics Inc | Métodos para la dosificación y el tratamiento de neoplasias malignas de linfocitos B en terapia celular adoptiva |
| CN110468210A (zh) * | 2019-09-12 | 2019-11-19 | 暨南大学 | Cdc45作为胶质母细胞瘤标志物及其作为治疗靶点的应用 |
| CN115398231A (zh) | 2019-12-06 | 2022-11-25 | 朱诺治疗学股份有限公司 | 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法 |
| CA3195511A1 (en) * | 2020-09-21 | 2022-03-24 | Hutchison Medipharma Limited | Heteroaromatic compounds and uses thereof |
| CN115969979B (zh) * | 2022-12-30 | 2025-08-29 | 中国人民解放军陆军军医大学第一附属医院 | C620-0580在制备抗胶质瘤药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101432281A (zh) * | 2006-04-19 | 2009-05-13 | 诺瓦提斯公司 | 6-o-取代的苯并唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法 |
| CN101466682A (zh) * | 2006-04-14 | 2009-06-24 | 阿斯利康(瑞典)有限公司 | 作为csf-1r激酶抑制剂的4-苯胺基喹啉-3-甲酰胺 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100721656B1 (ko) | 2005-11-01 | 2007-05-23 | 주식회사 엘지화학 | 유기 전기 소자 |
| PL2010528T3 (pl) | 2006-04-19 | 2018-03-30 | Novartis Ag | 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r |
| MX2008013531A (es) | 2006-04-20 | 2009-01-20 | Janssen Pharmaceutica Nv | Inhibidores de c-fms cinasa. |
| ES2452349T3 (es) * | 2007-05-21 | 2014-04-01 | Novartis Ag | Inhibidores de CSF-1R, composiciones, y métodos de uso |
-
2012
- 2012-05-04 CN CN201280021878.2A patent/CN103501785B/zh active Active
- 2012-05-04 PL PL12720761T patent/PL2704713T3/pl unknown
- 2012-05-04 HR HRP20170593TT patent/HRP20170593T1/hr unknown
- 2012-05-04 MX MX2013012939A patent/MX347616B/es active IP Right Grant
- 2012-05-04 LT LTEP12720761.1T patent/LT2704713T/lt unknown
- 2012-05-04 HU HUE12720761A patent/HUE032754T2/en unknown
- 2012-05-04 SI SI201230916A patent/SI2704713T1/sl unknown
- 2012-05-04 PT PT127207611T patent/PT2704713T/pt unknown
- 2012-05-04 CA CA2834696A patent/CA2834696C/en active Active
- 2012-05-04 ES ES12720761.1T patent/ES2622527T3/es active Active
- 2012-05-04 WO PCT/US2012/036589 patent/WO2012151523A1/en not_active Ceased
- 2012-05-04 BR BR112013028095-6A patent/BR112013028095B1/pt not_active IP Right Cessation
- 2012-05-04 DK DK12720761.1T patent/DK2704713T3/en active
- 2012-05-04 US US14/114,878 patent/US20140065141A1/en not_active Abandoned
- 2012-05-04 EA EA201391629A patent/EA023999B1/ru not_active IP Right Cessation
- 2012-05-04 EP EP12720761.1A patent/EP2704713B1/en active Active
- 2012-05-04 KR KR1020137031960A patent/KR101938431B1/ko not_active Expired - Fee Related
- 2012-05-04 JP JP2014509491A patent/JP6046702B2/ja active Active
-
2015
- 2015-06-29 US US14/754,152 patent/US20150306085A1/en not_active Abandoned
-
2017
- 2017-04-10 CY CY20171100426T patent/CY1119642T1/el unknown
-
2018
- 2018-06-04 US US15/996,945 patent/US10537561B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101466682A (zh) * | 2006-04-14 | 2009-06-24 | 阿斯利康(瑞典)有限公司 | 作为csf-1r激酶抑制剂的4-苯胺基喹啉-3-甲酰胺 |
| CN101432281A (zh) * | 2006-04-19 | 2009-05-13 | 诺瓦提斯公司 | 6-o-取代的苯并唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2704713B1 (en) | 2017-01-18 |
| EA023999B1 (ru) | 2016-08-31 |
| CN103501785A (zh) | 2014-01-08 |
| HUE032754T2 (en) | 2017-10-30 |
| AU2012250574B2 (en) | 2016-07-07 |
| CA2834696C (en) | 2019-07-23 |
| AU2012250574A1 (en) | 2013-11-28 |
| JP2014513136A (ja) | 2014-05-29 |
| WO2012151523A1 (en) | 2012-11-08 |
| CA2834696A1 (en) | 2012-11-08 |
| EA201391629A1 (ru) | 2016-01-29 |
| SI2704713T1 (sl) | 2017-05-31 |
| BR112013028095A2 (pt) | 2016-12-27 |
| MX347616B (es) | 2017-05-04 |
| ES2622527T3 (es) | 2017-07-06 |
| BR112013028095B1 (pt) | 2020-03-03 |
| CY1119642T1 (el) | 2018-04-04 |
| US20140065141A1 (en) | 2014-03-06 |
| MX2013012939A (es) | 2014-02-27 |
| AU2012250574A8 (en) | 2016-07-28 |
| US10537561B2 (en) | 2020-01-21 |
| KR20140029475A (ko) | 2014-03-10 |
| US20190030013A1 (en) | 2019-01-31 |
| US20150306085A1 (en) | 2015-10-29 |
| PT2704713T (pt) | 2017-04-24 |
| DK2704713T3 (en) | 2017-04-24 |
| LT2704713T (lt) | 2017-04-25 |
| KR101938431B1 (ko) | 2019-01-14 |
| HRP20170593T1 (hr) | 2017-07-14 |
| PL2704713T3 (pl) | 2017-08-31 |
| JP6046702B2 (ja) | 2016-12-21 |
| EP2704713A1 (en) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103501785B (zh) | 用于治疗脑肿瘤的csf-1r抑制剂 | |
| US11918558B2 (en) | Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia | |
| US11337983B2 (en) | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia | |
| BR112019017851A2 (pt) | método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo | |
| KR20200014790A (ko) | 난소암의 치료에 사용되는 티노스타무스틴 | |
| KR20200014789A (ko) | Tnbc 치료용 화합물 | |
| WO2019109074A1 (en) | Mebendazole cancer therapies and methods of use | |
| JP7586835B2 (ja) | ミトコンドリア標的化及び抗癌治療のためのアルキルｔｐｐ化合物 | |
| WO2012151541A1 (en) | Csf-1r inhibitors for treatment of brain tumors | |
| CN120676946A (zh) | Debio-0123与替莫唑胺和放射治疗组合用于治疗胶质瘤 | |
| AU2012250574B8 (en) | CSF-1R inhibitors for treatment of brain tumors | |
| US20260083707A1 (en) | Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia | |
| US9861615B2 (en) | Methods and pharmaceutical compositions for the treatment of beta-thalassemias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |